A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

This study is looking into a type of lung cancer called non-small cell lung cancer (NSCLC). This is the most common kind of lung cancer. The patients in this study have cancer that is either advanced (what doctors call Stage IIIB/IIIC), meaning it has grown quite a lot locally and can't be taken out with surgery or treated with certain types of strong radiation, or it has spread to other parts of the body (Stage IV), which is also known as metastatic cancer. Importantly, everyone in this study will not have had any treatment for their advanced lung cancer before.

The main goal of this study is to compare two different treatment approaches. One group of patients will receive a new medicine called tobemstomig, combined with traditional chemotherapy drugs like paclitaxel, pemetrexed, and carboplatin. The other group will receive a widely used treatment called pembrolizumab, also combined with these chemotherapy drugs. Both tobemstomig and pembrolizumab are types of immunotherapy, which work by helping your body's immune system fight cancer cells.

By comparing these two combinations, researchers hope to understand if tobemstomig plus chemotherapy is a better, safer, or equally effective treatment option for people with previously untreated advanced non-small cell lung cancer. They will be carefully watching to see how well the treatments shrink the cancer, how long they keep the cancer from growing, and what side effects people might have. This information will help doctors decide on the best treatments in the future.